Opioid-Marktprognose für den Nahen Osten und Afrika bis 2030 – Regionale Analyse – nach Produkt (Opioid mit sofortiger Wirkstofffreisetzung und Opioid mit langer Wirkstofffreisetzung und retardierter Wirkstofffreisetzung), Anwendung (Schmerzbehandlung, Anästhesie, Durchfall- und Hustenstillung, Entwöhnung und andere), Verabreichungsweg (oral, injizierbar und transdermales Pflaster) und Vertriebskanal (Krankenhausapotheken und Einzelhandelsapotheken)

BMIRE00031007 | Pages: 84 | Pharmaceuticals | Nov 2024 | Type: Regional | Status: Published

Der Opioidmarkt im Nahen Osten und Afrika wurde im Jahr 2022 auf 249,22 Millionen US-Dollar geschätzt und soll bis 2030 299,79 Millionen US-Dollar erreichen; es wird geschätzt, dass er von 2022 bis 2030 eine durchschnittliche jährliche Wachstumsrate von 2,3 % verzeichnet.

Steigende Fälle chronischer Schmerzen stärken den Opioidmarkt im Nahen Osten und Afrika

Chronische Krankheiten wie Herz-Kreislauf-Erkrankungen, Krebs, Erkrankungen des Bewegungsapparats und neurovaskuläre Erkrankungen beeinträchtigen die Gesundheit eines Menschen kritisch, indem sie die Immunität schwächen. Darüber hinaus leiden viele Patienten, die an diesen Krankheiten leiden, unter chronischen Schmerzen. Die oben genannten Krankheiten treten am häufigsten bei Erwachsenen und der geriatrischen Bevölkerung auf. Dennoch nehmen die Fälle dieser Krankheiten auch bei Kindern deutlich zu. Chronische Schmerzen treten auch häufig bei Sportlern, Athleten und Personen auf, die mit früheren Verletzungen leben. Laut einer im NCBI (National Center for Biotechnology Information) veröffentlichten Studie leiden weltweit 20 % aller Erwachsenen unter Schmerzen, und bei 10 % werden jährlich chronische Schmerzen diagnostiziert. Obwohl Schmerzen alle Bevölkerungsgruppen unabhängig von Geschlecht, Rasse/Ethnie, Einkommen, Alter oder geografischer Lage betreffen, sind sie weltweit nicht gleichmäßig verteilt. Verschreibungspflichtige Opioide, darunter Hydrocodon, Oxycodon und Morphin, sind wirksame schmerzstillende Medikamente, die zur Behandlung von Schmerzen eingesetzt werden, die durch Verletzungen, Operationen und Erkrankungen wie Krebs und Arthritis verursacht werden.

Laut dem Congressional Research Service erhalten Amerikaner möglicherweise mehr Opioide auf Kosten umfassenderer Schmerztherapien. Die vermehrte Verschreibung von Opioiden kann auf Versicherungserstattungsprogramme zurückgeführt werden, die Opioide gegenüber alternativen Schmerzbehandlungen begünstigen, auf Kostenstrukturen, die eine effizientere Versorgung fördern, und auf Beurteilungen, die Patientenzufriedenheit mit effektiver Schmerzbehandlung kombinieren. Aufgrund der Vorteile von Opioiden bei der Schmerzbehandlung steigt daher die Nachfrage bei Patienten mit chronischen Krankheiten.

Überblick über den Opioidmarkt im Nahen Osten und Afrika

Der Opioidmarkt im Nahen Osten und Afrika ist in Südafrika, die Vereinigten Arabischen Emirate, Saudi-Arabien und den Rest des Nahen Ostens und Afrikas unterteilt. Im Nahen Osten und Afrika werden Opioide zur Schmerzlinderung, Palliativversorgung und zur Entwöhnung von Opioiden eingesetzt. Der Behandlungsstandard bei Opioidkonsumstörungen umfasst die Behandlung mit Medikamenten wie Methadon, Buprenorphin oder Naltrexon; diese Medikamente gegen Opioidkonsumstörungen (MOUD) reduzieren Todesfälle durch Opioidüberdosierung. Im Jahr 2020 war MOUD nur im Libanon, in Marokko, im Iran und in den Palästinensischen Gebieten als Behandlungsform für Opioidkonsumstörungen verfügbar. Trotz der zunehmenden wirtschaftlichen und gesundheitlichen Entwicklung in einigen Ländern der Region gab es im Nahen Osten und in Afrika einen begrenzten Anstieg des Opioidkonsums.

Umsatz und Prognose des Opioidmarkts im Nahen Osten und Afrika bis 2030 (Mio. USD)

Segmentierung des Opioidmarkts im Nahen Osten und Afrika

Der Opioidmarkt im Nahen Osten und Afrika ist nach Produkt, Anwendung, Verabreichungsweg, Vertriebskanal und Land kategorisiert.

Basierend auf dem Produkt ist der Opioidmarkt im Nahen Osten und Afrika segmentiert in Opioid mit sofortiger Wirkstofffreisetzung und Opioid mit verlängerter Wirkstofffreisetzung und lang wirkendem Opioid. Das Segment der Opioid mit sofortiger Wirkstofffreisetzung und lang wirkendem Opioid hatte 2022 einen größeren Marktanteil. Das Opioid mit sofortiger Wirkstofffreisetzung und kurz wirkendem Opioid ist weiter unterteilt in Oxycodon, Hydrocodon, Tramadol, Codin, Propoxyphen und andere. Das Opioid mit verlängerter Wirkstofffreisetzung und lang wirkendem Opioid ist weiter unterteilt in Oxycodon, Fentanyl, Morphin, Methadon und andere.

In Bezug auf die Anwendung ist der Opioidmarkt im Nahen Osten und Afrika in Schmerzbehandlung, Anästhesie, Durchfallunterdrückung, Hustenunterdrückung, Entwöhnung und andere unterteilt. Das Segment Schmerzbehandlung hatte 2022 den größten Marktanteil.

Nach Verabreichungsweg ist der Opioidmarkt im Nahen Osten und Afrika in orale, injizierbare und transdermale Pflaster unterteilt. Das orale Segment hatte 2022 den größten Marktanteil.

Nach Vertriebskanal ist der Opioidmarkt im Nahen Osten und Afrika in Krankenhausapotheken und Einzelhandelsapotheken unterteilt. Das Segment Krankenhausapotheken hatte 2022 einen größeren Marktanteil.

Nach Ländern ist der Opioidmarkt im Nahen Osten und Afrika in Saudi-Arabien, Südafrika, die Vereinigten Arabischen Emirate und den Rest des Nahen Ostens und Afrikas unterteilt. Südafrika dominierte im Jahr 2022 den Opioidmarkt im Nahen Osten und in Afrika.

Neuraxpharm Pharmaceuticals SL, Endo International plc, Hikma Pharmaceuticals Plc, Mallinckrodt Plc, Rusan Pharma Ltd und Teva Pharmaceutical Industries Ltd sind einige der führenden Unternehmen auf dem Opioidmarkt im Nahen Osten und in Afrika.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Middle East & Africa Opioids Market - Key Market Dynamics

4.1 Market Drivers

4.1.1 Surging Chronic Pain Incidence

4.1.2 Increasing Geriatric Population

4.2 Market Restraints

4.2.1 Increasing Drug Abuse

4.3 Market Opportunities

4.3.1 Strategic Initiatives by Market Players

4.4 Impact of Drivers and Restraints:

5. Opioids Market - Middle East & Africa Analysis

5.1 Middle East & Africa Opioids Market Overview

5.2 Middle East & Africa Opioids Market Revenue (US$ Million), 2020-2030

5.3 Middle East & Africa Opioids Market Forecast Analysis

6. Middle East & Africa Opioids Market Analysis - by Product

6.1 Immediate Release Short Acting Opioid

6.1.1 Overview

6.1.2 Immediate Release Short Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

6.1.2.1 Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

6.2 Extended Release Long-Acting Opioid

6.2.1 Overview

6.2.2 Extended Release Long-Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

6.2.2.1 Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

7. Middle East & Africa Opioids Market Analysis - by Application

7.1 Pain Management

7.1.1 Overview

7.1.2 Pain Management: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

7.2 Anesthesia

7.2.1 Overview

7.2.2 Anesthesia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Diarrhea Suppression

7.3.1 Overview

7.3.2 Diarrhea Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Cough Suppression

7.4.1 Overview

7.4.2 Cough Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

7.5 De-Addiction

7.5.1 Overview

7.5.2 De-Addiction: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

7.6 Others

7.6.1 Overview

7.6.2 Others: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Opioids Market Analysis - by Route of Administration

8.1 Oral

8.1.1 Overview

8.1.2 Oral: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8.2 Injectable

8.2.1 Overview

8.2.2 Injectable: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Transdermal Patch

8.3.1 Overview

8.3.2 Transdermal Patch: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Opioids Market Analysis - by Distribution Channel

9.1 Hospital Pharmacies

9.1.1 Overview

9.1.2 Hospital Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

9.2 Retail Pharmacies

9.2.1 Overview

9.2.2 Retail Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Opioids Market - Country Analysis

10.1 Middle East & Africa

10.1.1 Middle East & Africa: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)

10.1.1.1 Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast Analysis - by Country

10.1.1.2 Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.2.1 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Product

10.1.1.2.2 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid

10.1.1.2.3 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid

10.1.1.2.4 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Application

10.1.1.2.5 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Route Of Administration

10.1.1.2.6 Saudi Arabia: Middle East & Africa Opioids Market Breakdown, by Distribution Channel

10.1.1.3 South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.3.1 South Africa: Middle East & Africa Opioids Market Breakdown, by Product

10.1.1.3.2 South Africa: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid

10.1.1.3.3 South Africa: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid

10.1.1.3.4 South Africa: Middle East & Africa Opioids Market Breakdown, by Application

10.1.1.3.5 South Africa: Middle East & Africa Opioids Market Breakdown, by Route Of Administration

10.1.1.3.6 South Africa: Middle East & Africa Opioids Market Breakdown, by Distribution Channel

10.1.1.4 United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.4.1 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Product

10.1.1.4.2 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid

10.1.1.4.3 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid

10.1.1.4.4 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Application

10.1.1.4.5 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Route Of Administration

10.1.1.4.6 United Arab Emirates: Middle East & Africa Opioids Market Breakdown, by Distribution Channel

10.1.1.5 Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

10.1.1.5.1 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Product

10.1.1.5.2 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Immediate Release Short Acting Opioid

10.1.1.5.3 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Extended Release Long Acting Opioid

10.1.1.5.4 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Application

10.1.1.5.5 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Route Of Administration

10.1.1.5.6 Rest of Middle East & Africa: Middle East & Africa Opioids Market Breakdown, by Distribution Channel

11. Industry Landscape

11.1 Overview

11.2 Growth Strategies in Opioids Market

11.3 Organic Growth Strategies

11.3.1 Overview

11.4 Inorganic Growth Strategies

11.4.1 Overview

12. Company Profiles

12.1 Endo International plc

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Mallinckrodt Plc

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Neuraxpharm Pharmaceuticals SL

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Hikma Pharmaceuticals Plc

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Rusan Pharma Ltd

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Teva Pharmaceutical Industries Ltd

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms

 

 

 

List of Tables

Table 1. Middle East & Africa Opioids Market Segmentation

Table 2. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Table 3. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product

Table 4. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

Table 5. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long-Acting Opioid

Table 6. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 7. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 8. Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 9. Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Country

Table 10. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product

Table 11. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

Table 12. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long Acting Opioid

Table 13. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 14. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route Of Administration

Table 15. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 16. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product

Table 17. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

Table 18. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long Acting Opioid

Table 19. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 20. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route Of Administration

Table 21. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 22. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product

Table 23. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

Table 24. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long Acting Opioid

Table 25. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 26. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration

Table 27. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 28. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Product

Table 29. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Immediate Release Short Acting Opioid

Table 30. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Extended Release Long Acting Opioid

Table 31. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Application

Table 32. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Route Of Administration

Table 33. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel

Table 34. Recent Organic Growth Strategies in Opioids Market

Table 35. Recent Inorganic Growth Strategies in the Opioids Market

Table 36. Glossary of Terms, Opioids Market

 

List of Figures

Figure 1. Middle East & Africa Opioids Market Segmentation, by Country

Figure 2. Middle East & Africa Opioids Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Middle East & Africa Opioids Market Revenue (US$ Million), 2020-2030

Figure 5. Middle East & Africa Opioids Market Share (%) - by Product (2022 and 2030)

Figure 6. Immediate Release Short Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Extended Release Long-Acting Opioid: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Middle East & Africa Opioids Market Share (%) - by Application (2022 and 2030)

Figure 9. Pain Management: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Anesthesia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 11. Diarrhea Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Cough Suppression: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. De-Addiction: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Others: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 15. Middle East & Africa Opioids Market Share (%) - by Route of Administration (2022 and 2030)

Figure 16. Oral: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Injectable: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Transdermal Patch: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 19. Middle East & Africa Opioids Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 20. Hospital Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Retail Pharmacies: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 22. Middle East & Africa Opioids Market, by Key Countries, Revenue (2022) (US$ Million)

Figure 23. Middle East & Africa: Opioids Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 24. Saudi Arabia: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. South Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 26. United Arab Emirates: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 27. Rest of Middle East & Africa: Middle East & Africa Opioids Market - Revenue and Forecast to 2030 (US$ Million)

Figure 28. Growth Strategies in Opioids Market

  1. Neuraxpharm Pharmaceuticals SL
  2. Endo International plc
  3. Hikma Pharmaceuticals Plc
  4. Mallinckrodt Plc
  5. Rusan Pharma Ltd
  6. Teva Pharmaceutical Industries Ltd
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa opioids market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa opioids market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa opioids market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2485
Site License
$4550
$3185
Enterprise License
$5550
$3885